Evidence map›Paper›PMID 26889497›Full record

ArticleJournal of virus eradication

Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection.

Jintanat Ananworanich, Carlo P Sacdalan, Suteeraporn Pinyakorn, Nicolas Chomont, Mark de Souza, Tassanee Luekasemsuk, Alexandra Schuetz, Shelly J Krebs, Robin Dewar, Linda Jagodzinski and 11 more

Open access · goldAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of virus eradication. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Activation of CXCR3Journal of virology · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 4 countries.

Jintanat AnanworanichSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Carlo P SacdalanSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Suteeraporn PinyakornSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nicolas ChomontDepartment of Microbiology, Infectiology, and Immunology, Université de Montréal, Faculty of Medicine, and Centre de Recherche du CHUM, Montreal, Quebec, Canada.
Mark de SouzaSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Tassanee LuekasemsukSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Alexandra SchuetzThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA; Armed Forces Research Institute of Medical Sciences, US Component, Bangkok, Thailand.
Shelly J KrebsThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Robin DewarLeidos Biomedical Research Inc, Virus Isolation and Serology Laboratory, Frederick, MD, USA.
Linda JagodzinskiThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Sasiwimol UbolyamHIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Rapee TrichavarojArmed Forces Research Institute of Medical Sciences, US Component, Bangkok, Thailand.
Sodsai TovanabutraThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Serena SpudichDepartment of Neurology, Yale University, New Haven, CT, USA.
Victor ValcourDepartment of Neurology, University of California, San Francisco, CA, USA.
Irini SeretiNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Nelson MichaelUnited States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Merlin RobbThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; United States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Praphan PhanuphakSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Jerome H KimUnited States Military HIV Research Program; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nittaya PhanuphakSEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Walter Reed Army Institute of Research · USThai Red Cross Society · THHIV Netherlands Australia Thailand Research Collaboration · THArmed Forces Research Institute of Medical Science · THCentre Hospitalier de l’Université de Montréal · CAHenry M. Jackson Foundation · USLeidos (United States) · USNational Institute of Allergy and Infectious Diseases · USUniversity of California, San Francisco · USYale University · US

Funding

Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) DiseaseZIAAI001121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SERETI, IRINI · 2010 to 2025
$27.2M
Long-Term CNS Consequences of Treatment During Acute InfectionR01MH095613 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPUDICH, SERENA S, VALCOUR, VICTOR · 2011 to 2015
$3.1M
The Latent HIV Reservoir in Early-treated Thai ChildrenR01AI114236 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI PUTHANAKIT, THANYAWEE, ROBB, MERLIN L · 2014 to 2018
$2.8M
Determinants of Resilience in Youth with HIV infection and Youth affected by HIVR01MH102151 · NIMH · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI ROBB, MERLIN L · 2014 to 2018
$2.3M
NIAID NIH HHS R01 AI114236NIMH NIH HHS R01 MH095613NIMH NIH HHS R01 MH102151
6 · The paper itself

Abstract

backgroundThe challenges of identifying acute HIV infection (AHI) have resulted in a lack of critical information on early AHI that constrains the development of therapeutics that are designed to eradicate HIV from the infected host.

methodsAHI participants were recruited from the Thai Red Cross Anonymous Clinic in Bangkok, Thailand into the RV254/SEARCH010 protocol and categorised according to Fiebig stages as follows: Fiebig I (HIV-RNA+, p24 Ag-, HIV IgM-) and Fiebig II-IV (HIV-RNA+, p24 Ag + or -, HIV IgM- or +, Western blot- or indeterminate). Proviral and viral burden and immune activation levels were compared between Fiebig stage groups at the time of AHI. CD4 and CD4/CD8 ratio were also compared between groups before and up to 96 weeks of ART.

resultsMedian age was 27 years and 96% were male. Fiebig I individuals had lower median HIV-DNA in mononuclear cells from blood (3

conclusionsCompared to later AHI stages, Fiebig I was associated with lower HIV burden in blood and tissue compartments, lower immune activation and higher CD4 and CD4/CD8 ratio. ART in Fiebig I-IV resulted in normalisation of CD4 cell count within the first year, supporting the benefit of early ART. However, the CD4/CD8 ratio was not normalised after 2 years of ART in all AHI stages, suggesting some degree of persistent immunological dysfunction even when ART was instituted as early as Fiebig I.

Indexed as

acute HIV infectionCD4CD4/CD8 ratioFiebig Iimmune activationreservoir

Identifiers

PMID26889497
PMCPMC4754199
OpenAlexW2417926799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.